Press Room

News / Nov 14, 2018

Hovione Ireland achieves the Business Working Responsibly mark for responsible and sustainable business practices

The Mark which is run by Business in the Community Ireland is valid for three years

Business Working Responsibly Mark | Hovione
From left to right: Kenneth Lloyd, Trevor Malone, John O’Neill, Marguerite Lynch, Linda Cullinane, Mary Hennessy and Louise Dennehy.
Business Working Responsibility Mark logo | Hovione

Hovione Ireland has achieved the Business Working Responsibly Mark for responsible and sustainable business practices. The Mark, developed by Business in the Community Ireland, and audited by the NSAI (National Standards Authority of Ireland), is based on ISO 26000. The Business Working Responsibly mark is the only independently audited standard for CSR and sustainability. Hovione is among a group of 33 companies who have achieved this award to date.

 

Irish Examiner writes an article about this mark Employee focus on ethical issues keeps companies on the righteous path

 

You might be also interested in:

 

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025